FN2 Earnings Intelligence
Jazz Pharmaceuticals plc income statement (quarterly)
Jazz Pharmaceuticals plc (JAZZ) Income Statement (quarterly) derived from persisted SEC financial facts.
Key Stats
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Market Cap | - | - | - | - | - |
| - Cash | $1,861.9 | $1,189.9 | $1,326.1 | $1,844.3 | $1,619.8 |
| + Debt | - | - | - | - | - |
| Enterprise Value | - | - | - | - | - |
| Revenue | $897.8 | $1,045.7 | $1,126.1 | $1,068.9 | $1,208.3 |
| % Growth | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| % Margin | - | - | - | - | - |
| EBITDA | -$45.5 | - | - | $345.7 | - |
| % Margin | -5.1% | - | - | 32.3% | - |
| Net Income | -$92.5 | -$718.5 | $251.4 | $293.1 | $192.8 |
| % Margin | -10.3% | -68.7% | 22.3% | 27.4% | 16.0% |
| Diluted EPS | -$1.52 | -$11.74 | $4.08 | $4.43 | $2.78 |
| % Growth | - | - | - | - | - |
| Operating Cash Flow | $429.8 | - | - | $408.2 | - |
| CapEx | $13.9 | - | - | $19.7 | - |
| Free Cash Flow | $415.9 | - | - | $388.5 | - |
Historical market capitalization is not persisted, so Market Cap and Enterprise Value remain unavailable rather than mixing today's market value into prior periods.
Income Statement
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue | $897.8 | $1,045.7 | $1,126.1 | $1,068.9 | $1,208.3 |
| Gross Profit | - | - | - | - | - |
| EBITDA | -$45.5 | - | - | $345.7 | - |
| Net Income | -$92.5 | -$718.5 | $251.4 | $293.1 | $192.8 |
| Diluted EPS | -$1.52 | -$11.74 | $4.08 | $4.43 | $2.78 |
Balance Sheet
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | $1,861.9 | $1,189.9 | $1,326.1 | $1,844.3 | $1,619.8 |
| Short-term Debt | - | - | - | - | - |
| Long-term Debt | $5,336.5 | $4,335.6 | $4,332 | $4,324.2 | $3,335 |
| Total Debt | - | - | - | - | - |
Cash Flow
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | $429.8 | - | - | $408.2 | - |
| Capital Expenditure | $13.9 | - | - | $19.7 | - |
| Free Cash Flow | $415.9 | - | - | $388.5 | - |
Ratios
USD in millions, except per-share values and percentages.
| Metric | 3/31/2025 | 6/30/2025 | 9/30/2025 | 3/31/2026 | 6/30/2026 |
|---|---|---|---|---|---|
| Revenue Growth | - | - | - | - | - |
| Gross Margin | - | - | - | - | - |
| EBITDA Margin | -5.1% | - | - | 32.3% | - |
| Net Margin | -10.3% | -68.7% | 22.3% | 27.4% | 16.0% |
| FCF Margin | 46.3% | - | - | 36.3% | - |
| Diluted EPS Growth | - | - | - | - | - |
Get the JAZZ recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.